Ribomic raised its forecast for standalone net income for the fiscal year ending March 2027 to a loss of ¥1.449 billion. The announcement was made after the close of trading on 20 October.
Ribomic revised its standalone earnings outlook for the fiscal year ending March 2027 to a forecast net loss of ¥1.449 billion. The change in the size of the loss compared with the previous forecast was disclosed.
The revision was announced after the close of trading on 20 October.